Calculate warfarin dose adjustments based on current INR, target range by indication, and weekly dose. Includes drug/food interaction tables, bleeding risk, and tablet strength reference.
The Warfarin Dosing Calculator provides INR-based dose adjustment guidance for patients on warfarin (Coumadin) therapy. It determines whether the current INR is within the target therapeutic range for the specific indication, calculates percentage dose adjustments based on published anticoagulation management protocols, and suggests the nearest available tablet strength. Warfarin remains one of the most widely prescribed medications worldwide, with over 30 million prescriptions annually in the United States alone.
Warfarin has one of the narrowest therapeutic indices of any commonly used drug — the difference between an effective anticoagulant dose and a dangerous hemorrhagic dose is small and varies dramatically between patients. Genetic polymorphisms in CYP2C9 (which metabolizes warfarin) and VKORC1 (the drug target) account for 30–50% of dose variability. Diet (vitamin K intake), concurrent medications (particularly CYP2C9 inhibitors like fluconazole and amiodarone), liver function, and thyroid status further modulate the response. This makes systematic dose titration with regular INR monitoring essential.
This calculator covers all major warfarin indications — atrial fibrillation, DVT/PE, mechanical heart valves, and antiphospholipid syndrome — with their evidence-based INR target ranges. It provides dose adjustment algorithms matching ACCP and CHEST guideline recommendations, vitamin K reversal guidance for supratherapeutic INRs, drug and food interaction reference tables, and a visual tablet strength guide for splitting/combining doses.
Warfarin dose adjustment requires integrating the current INR, target range, dose history, patient risk factors, and interacting medications. This calculator automates the percentage-based adjustment algorithm, preventing both under- and over-anticoagulation — the two most dangerous outcomes in warfarin management. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
Target ranges: AFib/DVT/PE: INR 2.0–3.0; Mechanical mitral valve: INR 2.5–3.5 Sub-therapeutic (INR < target): Increase weekly dose by 5–20% Supra-therapeutic (INR 3.5–5): Decrease by 10–15%, hold 1 dose Dangerous (INR 5–9): Hold 1–2 doses, decrease by 15–20% Critical (INR > 9): Hold warfarin, Vitamin K 2.5–5 mg PO
Result: Sub-therapeutic; Increase weekly dose by 5–15%: 38.5 mg/week (5.5 mg/day) → nearest tablet: 5 mg
A patient on 5 mg daily (35 mg/week) for atrial fibrillation with INR of 1.5 is below the 2.0–3.0 target range. The recommendation is to increase the weekly dose by approximately 10%, from 35 to 38.5 mg/week. The daily average of 5.5 mg rounds to the nearest available tablet strength of 5 mg, suggesting alternating 5 mg and 6 mg days.
Warfarin dose requirements vary 10-fold between patients, with approximately 30–50% of this variability explained by two genes: CYP2C9 (which metabolizes warfarin) and VKORC1 (the molecular target), plus clinical factors like age, weight, and race. CYP2C9 *2 and *3 variants reduce warfarin metabolism, requiring lower doses. VKORC1 -1639G>A determines warfarin sensitivity — the A allele (more common in Asians) requires lower doses, while the G allele requires higher doses. The FDA-approved warfarin label includes a pharmacogenomic dosing table, though routine genetic testing before starting warfarin is not yet standard practice in most settings.
When patients on chronic warfarin need surgery, the decision to "bridge" with heparin or low-molecular-weight heparin (LMWH) during the peri-operative warfarin-free period is complex. The BRIDGE trial (2015) showed that for patients with atrial fibrillation at moderate thrombotic risk, forgoing bridging therapy was non-inferior to bridging for preventing arterial thromboembolism and significantly reduced major bleeding. Current guidelines recommend bridging only for the highest-risk patients: mechanical mitral valves, recent (<3 months) DVT/PE, or prior stroke during warfarin interruption.
Home INR monitoring using portable coagulometers (e.g., CoaguChek) allows patients to self-test weekly and either self-adjust dosing or report to their anticoagulation clinic. Meta-analyses show that patient self-testing improves time in therapeutic range (TTR) from ~60% to ~70% and reduces thromboembolism by 50%. Medicare covers home INR testing devices for patients with mechanical heart valves, and some insurers extend coverage to other warfarin indications. Higher TTR is strongly associated with better clinical outcomes in all warfarin indications.
The target INR for atrial fibrillation is 2.0–3.0. This range provides optimal stroke prevention while minimizing bleeding risk. Below 2.0, stroke protection is inadequate. Above 3.0, bleeding risk increases without meaningful additional stroke reduction. The ideal midpoint target is 2.5.
During initiation: every 2–3 days until stable, then weekly for 1–2 weeks. Once stable in range: every 4 weeks (monthly). After any dose change: recheck in 3–7 days. After starting/stopping interacting drugs: recheck in 3–5 days. Some patients on long-term stable therapy can extend to every 6–8 weeks.
Vitamin K–rich foods (kale, spinach, broccoli, Brussels sprouts, green tea) can decrease INR. The key is consistency — patients don't need to avoid these foods, but should eat a consistent amount of vitamin K–containing foods each week. Sudden increases in green vegetable intake can drop INR; sudden decreases can raise it.
INR 3.5–5.0: hold 1 dose, slight decrease, recheck in a week. INR 5.0–9.0: hold 1–2 doses, decrease dose, recheck in 1–2 days. INR >9.0 without bleeding: hold warfarin, give vitamin K 2.5–5 mg orally, recheck in 24 hours. Active major bleeding at any INR: hold warfarin, give IV vitamin K 10 mg, 4-factor PCC (Kcentra), and consult hematology.
Warfarin brands (Coumadin vs. Jantoven vs. generic) can have slightly different bioavailability. While most patients tolerate switches, it is best to remain on the same manufacturer/brand consistently. If a switch occurs, recheck INR in 1–2 weeks.
Direct oral anticoagulants (DOACs: apixaban, rivarelbaban, dabigatran, edoxaban) don't require INR monitoring, have fewer food/drug interactions, and have fixed dosing. However, warfarin remains necessary for mechanical heart valves, severe hepatic impairment, antiphospholipid syndrome, and severe renal impairment. Warfarin is also much less expensive.